AngioDynamics (ANGO) Tops Q2 EPS by 5c, Revenues Beat; Offers FY19 EPS/Revenue Outlook
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/22/2026
- Nasdaq notches record-high close, AI optimism reignites and Treasury yields retreat
- Meta AI agent ‘Muse’ triggers massive tech rally as chips and Wall Street soar
- Oil price dips to $100 on hopes of US-Iran diplomacy, partial recovery in Saudi exports
- Paramount, Warner Bros jump on report of settlement progress in merger fight
- Investors may be underpricing how far rate hikes could go, Deutsche says
- Pennsylvania measles cases near 800 as outbreak grows
- A timeline of Trump administration moves to weaken endangered species protections
- Meta AI agent ‘Muse’ triggers massive tech rally as chips and Wall Street soar
- Nasdaq notches record-high close, AI optimism reignites and Treasury yields retreat
- SpaceX and Tesla’s AI linkup is getting deeper. Here’s what Morgan Stanley sees
AngioDynamics Reports Fiscal 2019 Second Quarter Financial Results
January 4, 2019 7:00 AM ESTFiscal 2019 Second Quarter Highlights
Net sales of $91.5 million, an increase of 5.5% year over year Gross margin expanded 440 basis points year over year to 53.7% GAAP EPS of $0.06 per share; adjusted EPS of $0.22 per share Cash provided by operations of $13.0 million; capital expenditures of $0.7 million Announced the acquisition of RadiaDyne and its proprietary OARtrac® radiation dose monitoring platform to build the Companys continuum of care within the oncology spaceLATHAM,... More
